Incorporating Somatuline’s generic approval headwinds
07/01/22 -"Despite easing pandemic headwinds and recovering underlying markets, our EPS estimates reset lower as we take on board Somatuline’s sales erosion on account of the approval of its generic in the US. ..."
Pages
52
Language
English
Published on
07/01/22
You may also be interested by these reports :
05/12/25
Against the backdrop of strong execution, with two outlook upgrades in 2025, backed by vigorous growth across all its focus areas (oncology, ...
28/11/25
Novo’s investors losing more weight than its patients
25/11/25
CureVac’s Q3 sales surpassed market expectations, driven by a one-off contribution from GSK. The operating profit benefited from the resolution of ...
25/11/25
Even though the sentiment around Novo has been extremely adverse (further exacerbated by today’s R&D development around Alzheimer’s), in our opinion, ...